It's good to hear of a young chip company pursuing wildly different applications with the same generic technology.
Lyric is prepping a product for data centre usage.
It also reckons genome sequencing is another use to which the technology can be put.
This multi-pronged approach to using a generic technology is a miles more sensible approach for a start-up than the overly-focussed approach many modern start-ups take.
It may seem sensible to focus scarce resources on a market niche - but it can easily be the wrong niche.
If the seed is scattered widely, it is more likely to find a fertile spot.
As for the excuse of lacking resources to pursue multi-markets - look at Lyric getting the military to give it $20 million to develop an application.
Customers have always funded chip technology development - if it's promising enough.

Leave a comment